Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 107

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 107
---
 definitive securities purchase
agreement, or the Securities Purchase Agreement, with certain institutional investors (including SilverArc Capital Management, Altium
Capital Management, LP and CVI Investments, Inc.), pursuant to which we issued and sold to such investors in a registered direct offering,
or the 2023 Offering, 850,000 ordinary shares, at a purchase price of $10.00 per share. Total gross proceeds to us from the offering were
$8,500,000. The total net proceeds after deducting placement agent fees and other offering expenses payable by us were $7.855 million.

We also entered into a letter agreement, or the Placement Agency
Agreement, with A. G. P./Alliance Global Partners, as sole placement agent, or the Placement Agent, dated July 17, 2023, pursuant to which
the Placement Agent agreed to serve as our placement agent in connection with the Offering. We paid the Placement Agent a cash placement
fee equal to 7.0% of the gross proceeds received for the ordinary shares sold in the Offering.

2024 Registered Direct Offering and Private Placement

On August 23, 2024, we entered into a definitive securities purchase
agreement, or the Securities Purchase Agreement, with an institutional investor, or the Investor, pursuant to which we issued and sold
to the Investor in a registered direct offering, or the 2024 Offering, (i) 265,000 ordinary shares, and (ii) pre-funded warrants, or the
Pre-Funded Warrants, to purchase up to 1,427,308 ordinary shares. The Pre-Funded Warrants have an exercise price of $0.0001 per ordinary
share, are immediately exercisable and may be exercised at any time until exercised in full.

In a concurrent private placement, or the Private Placement, we
also agreed to sell to the Investor unregistered Series A ordinary warrants to purchase up to 1,692,308 ordinary shares, or the Series
A Warrants, and unregistered Series B ordinary warrants to purchase up to 1,692,308 ordinary shares, or the Series B Warrants. Each ordinary
share (or Pre-Funded Warrant) is being sold with one Series A Warrant to purchase one ordinary share and one Series B Warrant to purchase
one ordinary share at a combined purchase price of $3.25. The Series A Warrants have an exercise price of $3.55 per share, are immediately
exercisable upon issuance